Dianthus Therapeutics Statistics
Total Valuation
DNTH has a market cap or net worth of $4.94 billion. The enterprise value is $3.72 billion.
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNTH has 54.67 million shares outstanding. The number of shares has increased by 16.27% in one year.
| Current Share Class | 54.67M |
| Shares Outstanding | 54.67M |
| Shares Change (YoY) | +16.27% |
| Shares Change (QoQ) | +6.81% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 92.85% |
| Float | 51.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,699.79 |
| Forward PS | n/a |
| PB Ratio | 4.11 |
| P/TBV Ratio | 4.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,783.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.25, with a Debt / Equity ratio of 0.00.
| Current Ratio | 29.25 |
| Quick Ratio | 29.06 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -22.70% and return on invested capital (ROIC) is -15.60%.
| Return on Equity (ROE) | -22.70% |
| Return on Assets (ROA) | -14.99% |
| Return on Invested Capital (ROIC) | -15.60% |
| Return on Capital Employed (ROCE) | -15.83% |
| Weighted Average Cost of Capital (WACC) | 4.74% |
| Revenue Per Employee | $14,522 |
| Profits Per Employee | -$1.89M |
| Employee Count | 92 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +319.58% in the last 52 weeks. The beta is 0.09, so DNTH's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +319.58% |
| 50-Day Moving Average | 81.11 |
| 200-Day Moving Average | 48.02 |
| Relative Strength Index (RSI) | 59.31 |
| Average Volume (20 Days) | 523,862 |
Short Selling Information
The latest short interest is 6.56 million, so 12.01% of the outstanding shares have been sold short.
| Short Interest | 6.56M |
| Short Previous Month | 9.07M |
| Short % of Shares Out | 12.01% |
| Short % of Float | 12.77% |
| Short Ratio (days to cover) | 6.26 |
Income Statement
In the last 12 months, DNTH had revenue of $1.34 million and -$173.66 million in losses. Loss per share was -$4.17.
| Revenue | 1.34M |
| Gross Profit | 1.34M |
| Operating Income | -191.29M |
| Pretax Income | -173.66M |
| Net Income | -173.66M |
| EBITDA | -191.17M |
| EBIT | -191.29M |
| Loss Per Share | -$4.17 |
Full Income StatementBalance Sheet
The company has $1.11 billion in cash and $1.36 million in debt, with a net cash position of $1.22 billion or $22.39 per share.
| Cash & Cash Equivalents | 1.11B |
| Total Debt | 1.36M |
| Net Cash | 1.22B |
| Net Cash Per Share | $22.39 |
| Equity (Book Value) | 1.20B |
| Book Value Per Share | 22.01 |
| Working Capital | 1.08B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$130.29 million and capital expenditures -$199,000, giving a free cash flow of -$130.49 million.
| Operating Cash Flow | -130.29M |
| Capital Expenditures | -199,000 |
| Depreciation & Amortization | 116,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -130.49M |
| FCF Per Share | -$2.39 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -14,318.04% |
| Pretax Margin | -12,998.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.27% |
| Shareholder Yield | -16.27% |
| Earnings Yield | -3.51% |
| FCF Yield | -2.64% |
Analyst Forecast
The average price target for DNTH is $121.17, which is 34.01% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $121.17 |
| Price Target Difference | 34.01% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 137.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNTH has an Altman Z-Score of 19.1 and a Piotroski F-Score of 2.
| Altman Z-Score | 19.1 |
| Piotroski F-Score | 2 |
